Cheshire, Connecticut-based Alexion Pharmaceuticals, Inc. ALXN released financial results on Thursday morning that beat Wall Street estimates.
Alexion Pharmaceuticals, Inc announced that its 4th quarter net income fell to $26.5 million, or 28 cents per share, down from $237.1 million, or $2.59 per share, a year earlier.
Excluding special items, the company reported earnings of 51 cents per share.
Alexion Pharmaceuticals, Inc reported revenue of $155.98 million, up from $110.65 million a year earlier.
According to a poll of analysts by Thomson Reuters, the average Wall Street estimate called for earnings of 50 cents per share, on revenue of $153.68 million.
Alexion Pharmaceuticals, Inc. (ALXN) finished the previous trading day at $86.12 per share. The consensus price target of analysts covering the company's stock is $84.78 per share.
Alexion Pharmaceuticals, Inc is engaged in the discovery, development and commercialization of therapeutic products aimed at treating patients with a wide array of severe disease states, including hematologic and kidney diseases, neurologic disorders, ophthalmic, transplant, other inflammatory disorders, and cancer.
Read more from Benzinga's Company news.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in